{
  "Country": "EN",
  "PICOs": [
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy, with an ECOG performance status of 0 or 1.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Objective response rate, overall survival, progression-free survival, health-related quality of life."
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy, with an ECOG performance status of 0 or 1.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel plus nintedanib",
      "Outcomes": "Objective response rate, overall survival, progression-free survival, health-related quality of life."
    }
  ],
  "SourceType": "hta_submission"
}